McCune-Albright syndrome

What changes during this transition

McCune-Albright syndrome (MAS) is a sporadic post-zygotic mosaic disorder caused by activating mutations in GNAS (GNAS1, encoding the α-subunit of the stimulatory G protein Gsα). It is not inherited — the mutation occurs after fertilization and distributes variably across tissues, which is why GNAS sequencing on peripheral blood is often negative and the diagnostic test requires affected-tissue sampling. The classic triad: (1) fibrous dysplasia of bone — monostotic, polyostotic, or panostotic — driving pain, fractures, deformities, cranial-nerve compression in skull-base disease, and scoliosis; (2) café-au-lait macules with characteristic 'coast of Maine' irregular borders, often midline-respecting and on the side of FD involvement; (3) hyperfunctioning endocrinopathies driven by constitutive Gsα-cAMP-PKA signaling — gonadotropin-independent peripheral precocious puberty (the most common endocrine manifestation; girls present with vaginal bleeding and breast development at very young ages, sometimes infancy; boys with testicular enlargement and autonomous androgen production), hyperthyroidism from a multinodular hyperfunctioning thyroid (~30-50%), GH-secreting pituitary adenoma driving acromegaly or pediatric gigantism (~10-20%), Cushing's syndrome from adrenal hyperplasia (neonatal-onset usually fatal if untreated), and FGF23-driven hypophosphatemic rickets / osteomalacia. Less common manifestations include hepatobiliary disease (cholestasis), cardiac arrhythmias and sudden death, pancreatic disease, and intestinal polyps. Diagnosis is clinical + radiologic (bone 'ground glass' appearance + skeletal survey + bone scintigraphy) + endocrine workup + GNAS sequencing on affected tissue. Standard of care: there is no cure for FD itself — management is supportive (orthopedic surgery for deformity and fracture management; IV bisphosphonates pamidronate or zoledronate to reduce bone turnover, though they don't reverse FD; denosumab in selected cases; pain management). Each hyperfunctioning endocrine axis is managed specifically: letrozole or tamoxifen plus a GnRH analog (after central puberty engages) for precocious puberty; methimazole, radioiodine, or thyroidectomy for hyperthyroidism; transsphenoidal surgery, somatostatin analogs, and the GH-receptor antagonist pegvisomant for acromegaly; surgical adrenalectomy for Cushing's; phosphorus and activated vitamin D for hypophosphatemia, with burosumab (Crysvita, anti-FGF23 antibody) FDA-approved for tumor-induced osteomalacia in selected cases. Surveillance is annual endocrine panel (TSH, IGF-1, cortisol, sex hormones, phosphate, 25-OH vitamin D, bone turnover markers), annual eye exam if skull-base FD (optic-nerve compression risk), periodic dental review if mandibular FD, audiology if temporal-bone FD, and baseline plus interval skeletal imaging. The FD Foundation and the McCune-Albright Network are the patient-advocacy anchors; Pediatric Endocrine Society and Endocrine Society guidelines cover clinical management. Editorial framing for the peptide library: MAS is typically diagnosed in early childhood (2-5 years is the typical age at diagnosis; some patients are diagnosed in infancy with neonatal Cushing's), and the syndrome carries lifelong bone fragility, precocious puberty causing psychological and social distress in very young children, and — when GH excess is present — extreme stature with cardiometabolic consequences. This is a heavy-burden multi-organ syndrome with family-level psychological weight, and the peptide-library posture reflects that: nothing in the current library has been characterized in MAS, and the GH-axis trio (CJC-1295, tesamorelin, ipamorelin) carries a specific Tier 2 contraindication because GHRH-receptor signaling at the somatotroph runs through Gsα-cAMP-PKA — the exact pathway MAS constitutively dysregulates. MAS is the third substrate in this library's cAMP-PKA-driver family (after Carney complex's PRKAR1A loss-of-function and Cushing's disease at the corticotroph) and it's the most direct: the GNAS-activating mutation IS the pathway driver. Combined with the ~10-20% baseline rate of GH-secreting pituitary adenoma and tesamorelin's labeled contraindication for pituitary tumor history, the GH-axis case in MAS is mechanistically wrong. BPC-157's angiogenic concern translates from the in-remission-cancer substrate because MAS IS multi-organ hyperfunctioning tissue, not an in-remission state. NMN's general-aging framing doesn't engage GNAS or any MAS pathway and lands awkwardly in a pediatric-onset syndrome. This browse entry exists for honest /ask grounding rather than discovery promotion — no peptide in the current library is editorially appropriate to elevate as a discovery card for the MAS population. Sixty-second deliberate non-elevation.